



Agenda

Subject to Change

Thursday, November 21, 2024

8:00am	Registration Check-in
9:30am – 11:30am	Advisory Boards Groups A & B Elite Platinum only
1:00pm – 3:00pm	Advisory Boards Groups C-D-E Elite Diamond only
4:30pm – 6:30pm	Advisory Boards Groups F-G-H Elite Diamond only
7:00pm – 9:00pm	VIP Reception with Key Opinion Leaders (KOLs) & Faculty Dinner By Invitation Only <i>Elite Diamond Sponsors Only</i>

Friday, November 22, 2024

7:30am	Registration Check-in
8:00am – 8:15am	Welcome & Introductions Chairs: Marina Garassino, MD, Christine Lovly, MD, PhD, Luis E. Raez, MD & Edgardo S. Santos, MD
Session I	Lung Cancer Screening, Smoking Cessation and Early Molecular Diagnosis
8:15am – 9:30am	Moderator: Luis E. Raez, MD
8:15am – 8:25am	Lung Cancer Screening Programs: How do We ‘Take it to the Next Level’ to Improve Lung Cancer Outcomes? Claudia I. Henschke, MD, PhD
8:25am – 8:35am	Existing and Emerging Tests for Cancer Interception: How Low do We have to Go (with the LOD)? Does Methylation Help? Triparna Sen, PhD

8:35am – 8:45am	Incidental Pulmonary Nodule Programs (IPNs) – What are Best Practices for Monitoring and Diagnosing? Gerard Silvestri, MD
8:45am – 8:55am	Assessing the Cancer Risk of Lung Nodules by Proteomic or Gene Expression Platforms Matthew Smeltzer, PhD
8:55am – 9:30am	Q & A Session Moderator: Luis E. Raez, MD Co-Moderator: Misty Shields, MD, PhD Panel: Henschke, Sen, Silvestri, Smeltzer
9:30am – 10:30am	Educational Plated Breakfasts (Non-CE) <i>Presented by Elite Diamond & Elite Platinum Sponsors</i> Sponsored Program Room 1 Sponsored Program Room 2 Sponsored Program Room 3
10:30am – 10:45am	Coffee Break Visit Industry Connections
Session II 10:45am – 11:45am	Early-Stage Resectable Lung Cancer Moderator: Mark Kris, MD
10:45am – 10:55am	What is the Best Way to Assess Response to Therapy? Is complete Pathologic Response the best surrogate? Lynette M. Sholl, MD
10:55am – 11:05am	Perioperative Chemo/Immunotherapy and Surgical Outcomes Jay M. Lee, MD
11:05am – 11:25am	Debate: Is Perioperative Immunotherapy the New Standard of Care?
11:05am - 11:15am	Yes: Rachel E. Sanborn, MD
11:15am – 11:25am	No: Hossein Borghaei, DO
11:25am – 11:35am	Which Patients Need Adjuvant Therapy? Karen Reckamp, MD
11:35am – 11:45am	Q & A Session Moderator: Mark Kris, MD Panel: Bradley, Hirsch, Sholl, Lee, Sanborn, Borghaei, Reckamp

Session III 11:45am – 12:50pm	Early-Stage NSCLC-Case-Based Panel Discussion Moderator: Karen Kelly, MD
11:45am – 12:00pm	Case #1: TBD Mary Jo Fidler, MD
12:00pm – 12:15pm	Case #2: TBD Erminia Massarelli, MD
12:15pm – 12:30pm	Case #3: TBD Hatim Husain, MD
12:30pm – 12:45pm	Case #4: TBD Jason Porter, MD
12:45pm – 12:50pm	Wrap-up Session Moderator: Karen Kelly, MD Panel: Carbone, Fidler, Massarelli, Husain, Porter
Session IV 12:50pm – 1:15pm	Keynote Presentation: Update Progress in Targeted Therapies for Early-Stage NSCLC Lyudmila Bazhenova, MD
1:15pm- 1:20pm	Questions and Answers Moderator: Luis E. Raez, MD
1:20pm – 2:20pm	Educational Lunches (Non-CE) <i>Elite Diamond & Platinum Sponsors</i> Sponsored Program Room 1 Sponsored Program Room 2 Sponsored Program Room 3
2:20pm – 2:35pm	Break Visit Industry Connections
Session V 2:35pm – 3:35pm	Locally Advanced NSCLC-Unresectable (Stage III) Moderator: Daniel Morgensztern, MD
2:35pm – 2:45pm	Assessing Resectability in Stage III NSCLC Linda Martin, MD
2:45pm – 2:55pm	Combining Immunotherapy with Radiation for LA-NSCLC Megan Daly, MD

2:55pm – 3:05pm	Moving the Bar Beyond PACIFIC. What is the Best Consolidation Therapy for People with Actionable and Non-Actionable Genes? Tom Stinchcombe, MD
3:05pm- 3:35pm	Q & A Session Moderator: Daniel Morgenstern, MD Co-Moderator: Rajat Thawani, MD Panel: Iyengar, Langer, Martin, Daly, Stinchcombe
Session VI 3:35pm – 4:40pm	Locally Advanced NSCLC-Unresectable Case-Based Panel Discussion Moderator: Corey Langer, MD
3:35pm – 3:45pm	Case #1: Localized Advanced NSCLC with Driver Mutation Raja Mudad, MD
3:45pm – 3:55pm	Case #2: Localized Advanced NSCLC without Driver Mutation Misty Shields, MD, PhD
3:55pm – 4:05pm	Case #3: Localized Advanced NSCLC with PDL-1 Zero Expression Wade Iams, MD
4:05pm – 4:15pm	Case #4: Localized Advanced NSCLC with Genetic Aberration Other Than EGFR or ALK Chul Kim, MD
4:15pm – 4:40pm	Wrap-up Session Moderator: Corey Langer, MD Panel: Bradley, Simon, Gadageel, Rodriguez, Mudad, Shields, Iams and Kim
4:40pm – 4:45pm	Meeting Adjourns Day 1 Luis E. Raez, MD
4:50pm – 6:50pm	Advisory Boards Groups I-J-K-L Elite Platinum
7:00pm – 9:00pm	VIP Reception with KOLs & Faculty Dinner <i>Elite Diamond Sponsors By Invitation Only</i>

Saturday, November 23, 2024

7:30am	Registration Check-in
8:00am – 8:05am	Welcome & Introductions Moderators: Marina Garassino, MD and Christine Lovly, MD, PhD
Session VII 8:05am – 9:20am	Small Cell Lung Cancer (SCLC) Moderator: Paul Bunn, MD
8:05am – 8:15am	Progress in Biomarkers for SCLC – Are We Ready for Implementation into Routine Clinical Practice? Ticiana Leal, MD
8:15am – 8:25am	Treatment for SCLC in 2024: Where Are We At? Christine L. Hann, MD
8:25am – 8:35am	The Future of SCLC Treatment: Potential Agents and Where Are We Going? Charles Rudin, MD, PhD
8:35am – 8:45am	Role of Radiation Therapy in SCLC Puneeth Iyengar, MD
9:05am – 9:20am	Q & A Session Moderator: Paul Bunn, MD Co-Moderator: Noura Choudhury, MD Panel: Leal, Hann, Rudin, Iyengar
9:20am – 10:20am	Educational Plated Breakfasts (Non-CE) <i>Presented by Diamond & Platinum Sponsors</i> Sponsored Program Room 1 Sponsored Program Room 2 Sponsored Program Room 3
10:20am – 10:35am	Break Visit Industry Connections
Session VIII 10:35am – 11:40am	Metastatic NSCLC with Genomic Alterations Case-Based Panel Discussion Moderator: Christine Lovly, MD, PhD
10:35am – 10:45am	Case #1: First line Therapy for EGFR-Mutant Lung Cancer Erminia Massarelli, MD

10:45am – 10:55am	Case #2: Progression After Third Generation EGFR TKI Jonathan Riess, MD
10:55am – 11:05am	Case #3: Treatment of Uncommon EGFR Mutations Xiuning Le, MD, PhD
11:05am – 11:15am	Case #4: First Line Therapy for ALK Positive Lung Cancer Julia Rotow, MD
11:15am – 11:25am	Case #5: Treatment Beyond Iorlatinib in ALK Positive Lung Cancer Jessica Lin, MD
11:25am – 11:35am	Case #6: Never Smoker with No Driver Alteration Elaine Shum, MD
11:35am – 11:40am	Wrap-up Session Moderator: Christine Lovly, MD, PhD Panel: Heymach, Hirsch, Massarelli, Riess, Le, Lin, Rotow, and Shum
Session IX 11:40am – 12:45pm	Metastatic NSCLC with Genomic Alterations-Case-Based Panel Discussion Moderator: Edgardo Santos, MD
11:40am – 11:50am	Case #1: ROS1 First Line or At Progression Justin Gainor, MD
11:50am -12:00pm	Case #2: RET First Line or a Progression Chul Kim, MD
12:00pm – 12:10pm	Case #3: MET First Line or a Progression Deborah Doroshaw, MD
12:10pm – 12:20pm	Case #4: Her2 Mutation First Line or a Progression Stephen Liu, MD
12:20pm – 12:30pm	Case #5: B-RAF No V600E First Line or At Progression Millie Das, MD
12:30pm – 12:40pm	Case #6: NTRK First Line Mary Jo Fidler, MD

12:40pm – 12:45pm	Wrap-up Session Moderator: Edgardo Santos, MD Panel: Sen, Heymach, Salgia, Gainor, Kim, Doroshaw, Liu, Das and Fidler
Session X 12:45pm – 1:10pm	Keynote Presentation The Era of Antibody-Drug Conjugates (ADCs) and Bi-Specifics Jyoti Patel, MD
1:10pm – 1:15 pm	Question and Answers Moderator: Marina Garassino, MD
1:15pm – 2:15pm	Educational Lunches (Non-CE) <i>Presented by Diamond & Platinum Sponsors</i> Sponsored Program Room 1 Sponsored Program Room 2 Sponsored Program Room 3
Session XI 2:20pm – 3:20pm	Drug Development Forum Pipeline Presentations in Lung Cancer (Non-CE) Moderator: Edgardo Santos, MD <i>10 min each Presented by Elite Diamond Sponsors</i> Elite Diamond Sponsor A Elite Diamond Sponsor B Elite Diamond Sponsor C Elite Diamond Sponsor D Elite Diamond Sponsor E Elite Diamond Sponsor F
3:20pm – 3:30pm	Break Visit Industry Connections
Session XII 3:30pm – 4:35pm	Metastatic NSCLC with Genomic Alterations Moderator: Christina Baik, MD
3:30pm – 3:40pm	Resistance to KRAS Inhibitors Matthew Gubens, MD
3:40pm – 3:50pm	STK11, KEAP and TP53 as Co-Mutations with Bad Prognosis - Is there a Predictive Role? Ferdinandos Skoulidis, MD, PhD
3:50pm – 4:00pm	Exon 20 Insertions - What Will be the Ideal Therapy? Zofia Piotrowska, MD

4:00pm – 4:10pm	BRAF and NTRK Inhibitors in NSCLC Liza C. Villaruz, MD
4:10pm - 4:35pm	Q & A Session Moderator: Christina Baik, MD Panel: Villaruz, Gubens, Piotrowska, Skoulidis
Session XIII 4:35pm – 5:55pm	Metastatic NSCLC without Genomic Alterations and the Impact of Smoking in the Outcome Case-Based Panel Discussion Moderator: Marina Garassino, MD
4:35pm – 4:45pm	Case #1: First-line Treatment of KRAS G12C Mutated Lung Cancer Tejas Patil, MD
4:45pm – 4:55pm	Case #2: First-Line Immunotherapy with STK11 or KEAP1 Mutations and PDL-1 >50% Adenocarcinoma Biagio Ricciuti, MD, PhD
4:55pm – 5:05pm	Case #3: First-Line Immunotherapy with STK11 or KEAP1 Mutations and PDL-1 0% Adenocarcinoma Nagla Karim, MD
5:05pm – 5:15pm	Case #4: Second-line After Chemo/Immunotherapy and on Maintenance IO (Non-Squamous Cell Carcinoma) Joshua Reuss, MD
5:15pm – 5:25pm	Case #5: First Line Immunotherapy with Squamous Histology and PDL-1 0% Jorge Gomez, MD
5:25pm – 5:35pm	Case #6: First Line with Squamous Histology and Asymptomatic (1-2 Subcentimeter Lesions) in the Brain, and PDL-1 35% (1-49%) Sonam Puri, MD
5:35pm – 5:45pm	Case #7: Second Line Therapy After Immunotherapy or Chemo/Immunotherapy in Squamous Cell Carcinoma Deborah Doroshow, MD, PhD
5:45pm – 5:55pm	Wrap-up Session Moderator: Marina Garassino, MD Panel: Carbone, Gadgeel, Rodriguez, Rotow, Patil, Ricciuti, Karim, Reuss, Gomez, Puri, Doroshow
5:55pm – 6:00pm	Meeting Adjourns Day 2 Christine Lovly, MD, PhD

6:00pm – 7:30pm

Sundowner Reception with KOLs

*Elite Platinum & Gold Sponsors | **By Invitation Only***

8:00pm – 10:00pm

Faculty Dinner

By invitation only

Sunday, November 24, 2024

7:00am – 9:00am

Farewell “Grab and Go” Breakfast for KOLs

7:00am – 9:00am

Post-Conference Advisory Boards or SWOTs

By invitation only